Display Settings:

Format

Send to:

Choose Destination

    Pediatr Infect Dis J. 2008 Jan;27(1):71-3.

    Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants.

    O'Brien KL, David AB, Chandran A, Moulton LH, Reid R, Weatherholtz R, Santosham M.

    Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. klobrien@jhsph.edu

    We report the phase III trial efficacy of 7-valent pneumococcal conjugate vaccine against clinical and culture proven otitis media (OM) among Navajo and White Mountain Apache infants. Efficacy was -0.4% (95% CI: -19.4 to 15.6) for clinically-diagnosed OM, 5.1% (95% CI: -51.5 to 40.6) for severe OM, and 64% (95% CI: -34% to 90%) for vaccine serotype pneumococcal OM suggesting that this vaccine is efficacious for pneumococcal OM in this high risk population.

    PMID: 18162944 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Pneumococcal Polysaccharide Vaccine (Pneumovax® 23)

      Pneumococcal disease is caused byStreptococcus pneumoniae bacteria. It is a leading cause of vaccine-preventable illness and death in the United States. Anyone can get pneumococcal disease, but some people are at greater...

    • Meningococcal Vaccine (Menomune®, Menactra®)

      Meningococcal disease is a serious bacterial illness. It is a leading cause of bacterial meningitis in children 2 through 18 years old in the United States.

    • Pneumococcal Conjugate Vaccine (Prevnar®)

      Infection withStreptococcus pneumoniae bacteria can cause serious illness and death. Invasive pneumococcal disease is responsible for about 200 deaths each year among children under 5 years old. It is the leading cause o...